{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:27:38Z","timestamp":1776922058206,"version":"3.51.2"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.bpg.2012.09.010","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T00:18:03Z","timestamp":1354148283000},"page":"531-548","source":"Crossref","is-referenced-by-count":42,"title":["Liver transplantation in the setting of chronic HCV"],"prefix":"10.1016","volume":"26","author":[{"given":"Norah","family":"Terrault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2012.09.010_bib1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib3","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/lt.20865","article-title":"Treating hepatitis C infection in liver transplant recipients","volume":"12","author":"Terrault","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib6","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.20947","article-title":"Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors","volume":"42","author":"Schiano","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib7","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/jhep.2002.31773","article-title":"Hepatitis C virus kinetics during and immediately after liver transplantation","volume":"35","author":"Garcia-Retortillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/lt.21117","article-title":"A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation","volume":"13","author":"Yilmaz","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hep.23240","article-title":"Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation","volume":"51","author":"Carrion","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jhep.2004.06.029","article-title":"Fibrosis progression after liver transplantation in patients with recurrent hepatitis C","volume":"41","author":"Neumann","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib11","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1213","article-title":"Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant","volume":"6","author":"Bacchetti","year":"2010","journal-title":"Int J Biostat"},{"key":"10.1016\/j.bpg.2012.09.010_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.21784","article-title":"The natural history of hepatitis C cirrhosis after liver transplantation","volume":"15","author":"Firpi","year":"2009","journal-title":"Liver Transplant"},{"issue":"supp 3","key":"10.1016\/j.bpg.2012.09.010_bib14","first-page":"A198","article-title":"Racial\/ethnic differences in survival and predictors of death among liver transplant (LT) with advanced fibrosis (AF) from hepatitis C virus (HCV)","volume":"12","author":"Valadao","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1053\/jhep.2000.17924","article-title":"Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation","volume":"32","author":"Berenguer","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/lt.500040401","article-title":"Cholestatic hepatitis C in liver allografts","volume":"4","author":"Taga","year":"1998","journal-title":"Liver Transplant Surg"},{"key":"10.1016\/j.bpg.2012.09.010_bib17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.24390","article-title":"Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men","volume":"54","author":"Lai","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1600-6143.2010.03037.x","article-title":"Liver transplantation in the United States, 1999-2008","volume":"10","author":"Thuluvath","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib19","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/lt.22461","article-title":"Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C","volume":"18","author":"Saxena","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0b013e318253f7fa","article-title":"Racial differences in fibrosis progression after HCV-related liver transplantation","volume":"94","author":"Layden","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/lt.23411","article-title":"Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection","volume":"18","author":"Terrault","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib22","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1600-6143.2012.04028.x","article-title":"Outcome of HCV\/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study","volume":"12","author":"Miro","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/lt.23402","article-title":"Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation","volume":"18","author":"Graziadei","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.24074","article-title":"Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection","volume":"53","author":"Charlton","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2010.10.037","article-title":"Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection","volume":"55","author":"Lange","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/TP.0b013e3182547551","article-title":"The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables","volume":"94","author":"Duarte-Rojo","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/jhep.2003.50278","article-title":"A model to predict severe HCV-related disease following liver transplantation","volume":"38","author":"Berenguer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/jlts.2002.32282","article-title":"Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C","volume":"8","author":"Burak","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1600-6143.2005.00741.x","article-title":"Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis","volume":"5","author":"Lake","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib30","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/lt.21668","article-title":"Report of the Paris consensus meeting on expanded criteria donors in liver transplantation","volume":"14","author":"Durand","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib31","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/lt.23396","article-title":"Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study","volume":"18","author":"Lai","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/TP.0b013e318219eb8f","article-title":"Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study","volume":"91","author":"Ballarin","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib33a","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/lt.20107","article-title":"Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation","volume":"10","author":"Machicao","year":"2004","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib33b","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/lt.21566","article-title":"Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis","volume":"15","author":"Briceno","year":"2009","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2011.03899.x","article-title":"Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN\/UNOS data","volume":"12","author":"Uemura","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/lt.22258","article-title":"Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus","volume":"17","author":"Taner","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/lt.22168","article-title":"Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts","volume":"16","author":"Tao","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.20995","article-title":"Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation","volume":"13","author":"Terrault","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib38","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/TP.0b013e3182472876","article-title":"Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation","volume":"93","author":"Bosch","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/01.TP.0000088668.28950.7C","article-title":"Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation","volume":"76","author":"Chopra","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/hep.510290122","article-title":"High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes","volume":"29","author":"Prieto","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/lt.21182","article-title":"Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study","volume":"13","author":"Klintmalm","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lt.23479","article-title":"Impact of sirolimus and tacrolimus on mortality & graft loss in liver transplant recipients with and without HCV \u2013 an analysis of the SRTR database","volume":"18","author":"Watt","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/j.1600-6143.2006.01382.x","article-title":"Mycophenolate mofetil use is associated with decreased risk of late acute rejection in adult liver transplant recipients","volume":"6","author":"Wiesner","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib44","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/lt.23381","article-title":"Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up","volume":"18","author":"Mangus","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib45","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1600-6143.2009.02642.x","article-title":"Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C","volume":"9","author":"Veldt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib46","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/lt.22389","article-title":"Hepatic steatosis at one year is an additional predictor of subsequent fibrosis severity in liver transplantation recipients with recurrent hepatitis C virus","volume":"17","author":"Brandman","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib47","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib48","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/lt.21890","article-title":"Evolution of hepatitis C virus in liver allografts","volume":"51","author":"Demetris","year":"2009","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0016-5085(94)95829-7","article-title":"Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection","volume":"106","author":"Lim","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib51","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib52","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/lt.21447","article-title":"Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus","volume":"14","author":"Fiel","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","article-title":"High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?","volume":"56","author":"Berardi","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2012.09.010_bib54a","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/lt.22460","article-title":"Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis","volume":"18","author":"Adebajo","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib54b","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1432-2277.2010.01142.x","article-title":"Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review","volume":"23","author":"Cholongitas","year":"2010","journal-title":"Transplant International"},{"key":"10.1016\/j.bpg.2012.09.010_bib55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/lt.20857","article-title":"Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation","volume":"12","author":"Carrion","year":"2006","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib56","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.21090","article-title":"Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation","volume":"43","author":"Blasco","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.gastro.2009.09.047","article-title":"Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation","volume":"138","author":"Carrion","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib58","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/lt.21508","article-title":"Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C","volume":"14","author":"Pungpapong","year":"2008","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib59","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1053\/jlts.2003.50255","article-title":"Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation","volume":"9","author":"Terrault","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib60","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/lt.22271","article-title":"PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus","volume":"17","author":"Bzowej","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib61","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2036.2008.03680.x","article-title":"Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics","volume":"27","author":"Tekin","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2012.09.010_bib62","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.20793","article-title":"Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy","volume":"42","author":"Everson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib63","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/TP.0b013e3181b2e0d1","article-title":"An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant","volume":"88","author":"Massoumi","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib64","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2008.11.015","article-title":"Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study","volume":"50","author":"Carrion","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib65","unstructured":"Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown Jr RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology, in press."},{"key":"10.1016\/j.bpg.2012.09.010_bib66","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","article-title":"Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study","volume":"46","author":"Iacobellis","year":"2007","journal-title":"J Hepatol"},{"issue":"S2","key":"10.1016\/j.bpg.2012.09.010_bib67","first-page":"A8","article-title":"Real-life safety of telaprevir and boceprevir combination with peginterferon alfa\/ribavirin, in cirrhotic non responders. Results of the French early access program","volume":"56","author":"Hezode","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib68","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib69","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1053\/jlts.2002.34968","article-title":"Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C","volume":"8","author":"Firpi","year":"2002","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib70","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2893.2008.01019.x","article-title":"Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies","volume":"15","author":"Xirouchakis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bpg.2012.09.010_bib71","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib72","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib73","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","article-title":"Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C","volume":"139","author":"Fukuhara","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib74","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1600-6143.2011.03491.x","article-title":"Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation","volume":"11","author":"Coto-Llerena","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib75","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1440-1746.2012.07129.x","article-title":"IL28B SNP of donors and recipients can predict virological response to PEGIFN\/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation","volume":"27","author":"Kawaoka","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib76","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib77","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MCG.0b013e31825833be","article-title":"Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation","volume":"46","author":"Gordon","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2012.09.010_bib78","doi-asserted-by":"crossref","DOI":"10.1097\/00042737-200411000-00020","article-title":"Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy","volume":"16","author":"Berenguer","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib79","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-6143.2006.01619.x","article-title":"Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation","volume":"7","author":"Bizollon","year":"2007","journal-title":"Am J Transplant"},{"issue":"S1","key":"10.1016\/j.bpg.2012.09.010_bib80","first-page":"LB2","article-title":"Histologic response to anti-viral therapy confers a mortality benefit in virologic non-responders after liver transplantation","volume":"18","author":"Flemming","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib81","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.dld.2012.06.013","article-title":"Long-term antiviral treatment for recurrent hepatitis C after liver transplantation","volume":"44","author":"Bertuzzo","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.bpg.2012.09.010_bib82","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/hep.25831","article-title":"Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers","volume":"56","author":"Hulskotte","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.24443","article-title":"Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus","volume":"54","author":"Garg","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib84","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"issue":"S2","key":"10.1016\/j.bpg.2012.09.010_bib85","first-page":"A47","article-title":"Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience","volume":"56","author":"Coilly","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib86","article-title":"Early experience with triple therapy in patients on cyclosporine A for hepatitis C recurrence after liver transplantation","volume":"18","author":"Martinez","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib87","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/lt.23482","article-title":"A case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis c following liver retransplantation","volume":"18","author":"Fontana","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib88","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","article-title":"Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon","volume":"142","author":"Levitsky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2012.09.010_bib89","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1053\/jlts.2003.50233","article-title":"Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection","volume":"9","author":"Kugelmas","year":"2003","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib90","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.20005","article-title":"Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores","volume":"39","author":"Yao","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib91","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jhep.2010.06.006","article-title":"Retransplantation in patients with hepatitis C recurrence after liver transplantation","volume":"53","author":"Carrion","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.bpg.2012.09.010_bib92","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/jhep.2003.50328","article-title":"Validation and refinement of survival models for liver retransplantation","volume":"38","author":"Rosen","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2012.09.010_bib93","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1600-6143.2007.02082.x","article-title":"Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection","volume":"8","author":"Ghabril","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib94","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/lt.21322","article-title":"Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study","volume":"13","author":"McCashland","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib95","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/TP.0b013e318246f8b3","article-title":"A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis","volume":"93","author":"Andres","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib96","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1097\/01.tp.0000203798.96491.2f","article-title":"Liver retransplantation: a model for determining long-term survival","volume":"81","author":"Linhares","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2012.09.010_bib97","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1600-6143.2007.01887.x","article-title":"Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index","volume":"7","author":"Northup","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.bpg.2012.09.010_bib98","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/lt.21954","article-title":"Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course","volume":"15","author":"Gallegos-Orozco","year":"2009","journal-title":"Liver Transplant"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691812000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T23:28:26Z","timestamp":1540078106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691812000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S1521691812000935"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.09.010","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}